Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table A25–1 Incidence of Group B Streptococcus Infection in Noninfants and Nonpregnant Women

Age Groups

Population

Incidence Rates (per 100,000)

Cases

<1

3,963,000

0.00

0

1–4

16,219,000

0.92

149

5–14

38,056,000

0.91

347

15–24

36,263,000

1.70

616

25–34

41,670,000

1.76

731

35–44

42,149,000

1.68

708

45–54

30,224,000

4.84

1,464

55–64

21,241,000

8.31

1,766

65–74

18,964,000

11.57

2,194

75–84

11,088,000

22.69

2,516

85+

3,598,000

22.70

817

Total

263,435,000

4.29

11,308

with GBS experience invasive disease (e.g., bacteremia, sepsis, soft tissue infections) associated with 19 days at an HUI of .66. See Table A25–2.

COST INCURRED BY DISEASE

Table A25–3 summarizes the health care costs incurred by GBS infections. For the purposes of the calculations in this report, it was assumed that GBS infections in pregnant women are associated with additional hospitalization at the time of delivery and associated inpatient and outpatient physician visits and medication. Costs are also included for screening for GBS and chemoprophylaxis of pregnant women. It was estimated that all nonpregnant adults with invasive GBS disease require hospitalization (including inpatient physician visits) and outpatient services as well.

For the calculation in this report, it was assumed that all infants with GBS require hospitalization, including multiple inpatient physician visits and diagnostics. It was assumed that a small percentage of infants with GBS meningitis will require long-term care for 10 years until death.

VACCINE DEVELOPMENT

The committee assumed that it will take 7 years until licensure of a GBS vaccine and that $300 million needs to be invested for approval for use in nonpregnant people, and an additional $100 million needs to be invested for that same vaccine to be used in pregnant women. Special considerations regarding



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement